Mining and analysis of prognosis-related mutant gene groups in non-small cell lung cancer based on the Cancer Genome Atlas
Objective Based on the Cancer Genome Atlas(TCGA),the correlation between mutated genes and the clinical prognosis of non-small cell lung cancer(NSCLC)was explored,in order to provide sensitive and effective biomarkers for the prognosis of NSCLC.Methods On May 25,2021,the data of patients diagnosed with NSCLC was downloaded from TCGA(https://portal.gdc.cancer.gov/),including 924 patients with lung adenocarcinoma(LUAD)(433 patients with single nu-cleotide variant[SNV]data,535 cancer tissues and 59 normal tissues with mRNA expression information)and 994 lung squamous cell carcinoma(LUSC)patients(475 SNV data,502 cancer tissues and 49 normal tissues with mRNA expression information).The waterfall map and Wilcoxon test method were used to mine and analyze the genes with high mutation fre-quency in NSCLC patients and which could significantly affect their expression.Finally,Kaplan-Meier survival analysis was performed to find genes that could serve as prognostic markers for NSCLC.Results In LUAD,the mutation frequency of tumor protein P53(TP53),myocardial Ranidine receptor 2(RYR2)and low density lipoprotein receptor-associated pro-tein 1B(LRPIB)genes were high,and the mRNA expression after mutation was lower than that of wild-type patients,with statistical significance(P＜0.05).In LUSC,the mutation frequency of LRP1B and Xin-containing actin binding repeat pro-tein 2(XIRP2)gene was high,and mRNA expression after mutation was lower than that of wild-type patients,with statisti-cal significance(P＜0.05).However,only TP53 mutation could be used as clinical prognostic marker for lung adenocarci-noma,and LRP1B mutation could be used as clinical prognostic marker for lung squamous cell carcinoma by Kaplan-Meier survival analysis.Conclusion TP53 and LRP1B mutations can be used as prognostic markers for LUAD and LUSC,respectively.
The Cancer Genome AtlasNon-small cell lungMutationPrognosis
万方数据
维普
